RxDoctor Payments DataLook up a doctor →

William Calley, MD

Family Practice · Garland, TXNPI 1467763961

Payments from drug & device makers

$7,056in general payments, 2019–2025

Across 427 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$827
  • GSK$596
  • Pfizer$542
  • AstraZeneca$535
  • Novo Nordisk$433
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,056 in reported general payments places this provider in the 95th percentile of 646 family practice providers in Texas.

See all family practice providers in Texas

Medicare billing

Part B allowed, 2024
$124,035
Medicare patients
391
Services billed
3,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$63,309
OzempicSemaglutide54$53,022
Nurtec OdtRimegepant Sulfate14$28,357
Repatha SureclickEvolocumab25$23,648
MounjaroTirzepatide11$23,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,469
TrulicityDulaglutide17$15,876
Janumet XrSitagliptin Phos/Metformin Hcl18$13,720
PremarinEstrogens, Conjugated24$7,053
SynthroidLevothyroxine Sodium91$7,027
Praluent PenAlirocumab13$6,744
OxycontinOxycodone Hcl12$3,741
Dexlansoprazole DrDexlansoprazole14$2,926
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$2,814
ValacyclovirValacyclovir Hcl38$2,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$78$63,30970 claims
Novo NordiskOzempic$433$53,02254 claims
Lilly USA, LLCMounjaro, Trulicity$274$39,50128 claims
PfizerNurtec Odt, Premarin, Paxlovid$542$36,83952 claims
GSKTrelegy Ellipta$596$21,46933 claims
MerckJanumet Xr$345$13,72018 claims
AbbVieSynthroid$1,300$7,02791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 646 family practice providers in Texas.

Other family practice in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →